Kala Bio said it expects to ship its first commercial AI product in about 14 days. The company said its Researgency.ai platform is live and positioned to target an AI-in-healthcare market projected to exceed USD 180 billion by 2030. Kala Bio cited Gartner data showing a 1,445% increase in enterprise inquiries about multi-agent AI systems from Q1 2024 to Q2 2025.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kala Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603110630PRIMZONEFULLFEED9669863) on March 11, 2026, and is solely responsible for the information contained therein.
Comments